A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Key facts

Sponsor

Oncternal Therapeutics, Inc

Principal Investigator

Michael Choi, MD

University of California, San Diego

Intervention

Cirmtuzumab (2-16 kg/mg) plus Ibrutinib(drug)

Enrollment

95 enrolled

Eligibility

18 years · All sexes

Timeline

2018 – 2024

Study locations (12)

• City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
• Sanford Stem Cell Clinical Center at UCSD, La Jolla, California, United States
• UC Davis Comprehensive Cancer Center, Sacramento, California, United States
• Yale Cancer Center, New Haven, Connecticut, United States
• Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
• Louisiana State University Health New Orleans (NCI Community Oncology Research Program), New Orleans, Louisiana, United States
• Hackensack Meridian Health, John Theurer Cancer Center, Hackensack, New Jersey, United States
• Northwell Health, New Hyde Park, New York, United States
• Manhattan Hematology Oncology Research Foundation, Inc., New York, New York, United States
• Columbia University Medical Center, New York, New York, United States
• The Christ Hospital Lindner Research Center, Cincinnati, Ohio, United States
• MD Anderson Cancer Center, Houston, Texas, United States

Collaborators

California Institute for Regenerative Medicine (CIRM) · University of California, San Diego · Pharmacyclics LLC.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07194980
  Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Fred Hutchinson Cancer Center
• RECRUITINGEARLY PHASE1NCT07428707
  Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
  National Heart, Lung, and Blood Institute (NHLBI)
• RECRUITINGPHASE4NCT07218341
  A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Eli Lilly and Company
• RECRUITINGPHASE1NCT06859008
  Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  City of Hope Medical Center
• RECRUITINGPHASE2NCT07271667
  A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
  Curis, Inc.
• RECRUITINGPHASE2NCT07014917
  Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
  Zulfa Omer
• RECRUITINGPHASE2NCT06958705
  Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
  The First Affiliated Hospital with Nanjing Medical University
• RECRUITINGPHASE1, PHASE2NCT07052695
  Mosunetuzumab for CLL MRD Clearance
  Inhye Ahn

See all trials for B-cell chronic lymphocytic leukemia →